GRAIL, LLC
1525 O'Brien Drive
Menlo Park
California
94025
United States
Tel: 833-694-2553
Website: https://grail.com/
Email: customerservice@grail.com
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
LEADERSHIP:
CEO: Bob Ragusa
91 articles with GRAIL, LLC
-
GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
1/11/2021
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect
-
New Research Suggests Multi-Cancer Early Detection Blood Test Could Reduce Late-Stage Cancer Diagnoses by More Than Half
12/16/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today released new analyses estimating the potential of GRAIL’s multi-cancer early detection blood test to find more cancers earlier and save lives.
-
California-based Grail aims to alter the devastating trajectory of cancer mortality with the addition of one simple blood test.
-
GRAIL and UK Government to Make Galleri Multi-Cancer Early Detection Blood Test Available to Patients
11/27/2020
Agreement Aims to Help UK Meet its Goal of Diagnosing Three-Quarters of All Cancers at an Early Stage by 2028
-
Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC).
-
GRAIL Announces Filing of Registration Statement for Proposed Initial Public Offering
9/9/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States.
-
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
-
GRAIL to Present New Data Supporting its Multi-Cancer Early Detection Test at the American Association for Cancer Research (AACR) Annual Meeting II
6/22/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II. Today, the majority of deadly cancers go undetected until they have progressed to late stages, when chances of survival are much lower. This is bec
-
GRAIL to Participate in BofA Securities 2020 Health Care Conference
5/7/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced executives will be speaking at the BofA Securities 2020 Health Care Conference.
-
GRAIL Announces $390 Million Series D Financing
5/6/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced a $390 million Series D financing round.
-
Mostafa Ronaghi Joins GRAIL’s Board of Directors
5/4/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced Mostafa Ronaghi, PhD, joined the GRAIL Board of Directors.
-
GRAIL Appoints Satnam Alag as Senior Vice President of Software Engineering
4/29/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced the appointment of Satnam Alag, PhD, as Senior Vice President of Software Engineering.
-
In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.
-
GRAIL to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting
4/27/2020
Findings Demonstrate Strong Performance of GRAIL’s Multi-Cancer Early Detection Blood Test in Patients with Suspicion of Cancer
-
GRAIL Appoints Sir Harpal Kumar as President of GRAIL Europe
4/10/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Sir Harpal Kumar as President of GRAIL Europe. In this new role, Sir Harpal will be responsible for leading GRAIL’s entry and growth in Europe. “I am delighted to welcome Harpal to the GRAIL team. He is a passionate advocate for better outcomes in cancer, with a widely recognized ap
-
GRAIL Announces Validation of Its Multi-Cancer Early Detection Test Published in Annals of Oncology
3/31/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced validation data for its multi-cancer early detection blood test were published in Annals of Oncology.
-
GRAIL Initiates First Interventional Study Using its Multi-Cancer Early Detection Test to Guide Clinical Care
2/18/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the initiation of the PATHFINDER Study.
-
GRAIL Appoints Gautam Kollu as Chief Commercial Officer
12/16/2019
Mr. Kollu joins GRAIL from Illumina, Inc. where he most recently served as Vice President, Global Market Development and led the teams that drove the commercial adoption of genomics in multiple applications including noninvasive prenatal testing and liquid biopsy.
-
GRAIL Appoints Matthew Young as Chief Operating Officer and Chief Financial Officer
10/8/2019
GRAIL, Inc. announced that Matthew P. Young has been appointed Chief Operating Officer and Chief Financial Officer effective October 28, 2019.
-
CORRECTING and REPLACING GRAIL Announces Positive Validation Data for Its Multi-Cancer Early Detection Test
10/7/2019
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced new data validating the performance of its investigational multi-cancer early detection blood test for the first time in an independent cohort of participants.